Premium
Inside Cover: An iGlu Receptor Antagonist and Its Simultaneous Use with an Anticancer Drug for Cancer Therapy (Chem. Eur. J. 16/2015)
Author(s) -
Tan Si Yu,
Ang Chung Yen,
Luo Zhong,
Li Peizhou,
Nguyen Kim Truc,
Zhao Yanli
Publication year - 2015
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201590063
Subject(s) - pharmacology , anticancer drug , antagonist , doxorubicin , cancer therapy , cancer , drug , mesoporous silica , medicine , chemistry , receptor , chemotherapy , mesoporous material , biochemistry , catalysis
A combination therapy using a neuroprotective drug, N ‐(4‐hydroxylphenylacetyl) spermine, and an anticancer drug, doxorubicin, integrated with functional mesoporous silica nanoparticles as carriers has been developed for improved treatment of metastatic melanoma cancer, as reported by Y. Zhao et al. in their Full Paper on page 6123 ff.